Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the
last 20 years, much experience has been gained in measurement and interpretation of these …

Key Clinical Points Postmenopausal Osteoporosis Fragility fractures are very common
among postmenopausal women and are associated with increased morbidity, mortality, and …

Context Denosumab discontinuation is characterized by an increase in bone turnover
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral …

Background No clinical trials have compared osteoporosis drugs with incident fractures as
the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate …

The fully human monoclonal antibody denosumab was approved for treatment of
osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces …

With the reignited push for manned spaceflight and the development of companies focused
on commercializing spaceflight, increased human ventures into space are inevitable …

The adult bone is continuously being remodelled to repair microdamage, preserve bone
strength and mechanical competence as well as maintain calcium homeostasis. Bone …

Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …

Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …

Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the …